Testicular type II germ cell cancers (GCCs) arise from a developmentally arrested primordial germ cell (PGC), which develops into a precursor lesion, termed as germ cell neoplasia *in situ* (GCNIS) ([@bib19]; [@bib23]; [@bib2]). GCNIS cells eventually into a seminoma or non-seminoma. PGCs, GCNIS and seminomas are highly similar with regard to morphology and gene expression. They express the germ cell markers SOX17, cKIT, TFAP2C and PRDM1, as well as the pluripotency markers NANOG, OCT3/4 and LIN28A ([@bib3]). Seminomas grow uniformly as flat, big, roundish cells with a big nucleus and present as weakly eosinophilic. The stem cell-like population of the non-seminomas is termed embryonal carcinoma (EC), which is pluri- to totipotent and able to differentiate into teratomas (composed of cells of all three germ layers), as well as yolk-sac tumours and choriocarcinomas (extraembryonic tissues; [@bib19]). In contrast to PGCs, GCNIS and seminomas, ECs express the pluripotency factor SOX2 instead of SOX17 ([@bib4]). SOX17 is a key determinant of murine PGC specification and controls expression of PGC-associated genes, like Prdm1 (Blimp1), Prdm14 and Tfap2c ([@bib20]; [@bib10]; [@bib26]). In murine embryonic stem cells, the transcription factor SOX2 partners with OCT3/4 and binds to a canonical binding motif, thereby regulating expression of pluripotency factors ([@bib1]). Interestingly, overexpression of Sox17 in murine embryonic stem cells leads to a shift of binding of OCT3/4 from SOX2 to SOX17, resulting in targeting a compressed motif within genes, which are associated with endodermal differentiation ([@bib1]). Interestingly, human PGCs, GCNIS and seminoma cells are not prone to spontaneous differentiation, although expressing SOX17.

About 225 genes are classified as cancer/testis-antigens (CTA), which are exclusively expressed in cancer cells or testis tissue, but not in any other somatic cell type ([@bib8]). The molecular roles of CTAs are poorly understood, but due to their unique expression pattern CTAs are discussed to serve as modulators of gene expression and cell cycle in tumour cells, as well as regulators of spermatogenesis. In addition, CTA might be targets for immune-based therapies ([@bib31]).

The CTA PRAME (preferentially expressed antigen in melanoma) is found overexpressed in various cancer types, including melanoma, neuroblastoma and breast cancers ([@bib27]; [@bib28]; [@bib17]).

In a previous study, we found *PRAME* highly expressed in the seminoma cell line TCam-2, whereas the EC cell line 2102EP lacked PRAME expression ([@bib15]). In addition, during *in vivo* reprogramming of TCam-2 to an EC-like cell fate *PRAME* and *SOX17* are downregulated ([@bib15]). Furthermore, in GCNIS cells, seminomas and PGCs *PRAME* expression correlates to SOX17 expression. So, we reasoned that expression of *PRAME* is a general feature of PGC, GCNIS and seminomas and its function might be linked to SOX17.

Expression of *PRAME* has been shown to be regulated by DNA methylation and the chromatin state ([@bib21]). PRAME inhibits retinoic acid (RA) signalling by binding the RAR/RXR receptors, thereby preventing ligand-induced receptor dimerisation and downstream effector activation ([@bib6]). In melanoma cells, RA-mediated differentiation is restored after RNAi-mediated knockdown of *PRAME* ([@bib6]). The seminoma-like cell line TCam-2 is resistant towards RA-induced differentiation ([@bib12]), whereas EC cell lines differentiate in response to RA into cells of all three germ layers ([@bib24]; [@bib12]). We found that the CTA *PRAME* is differentially methylated (5mC) between seminoma-like TCam-2 (*PRAME* 5mC low) and EC-like 2102EP (*PRAME* 5mC high; [@bib15]). Thus, we further speculate that *PRAME* might be required for RA resistance of PGCs/seminomas.

In this study, we analysed molecular function of *PRAME* and its link to SOX17 in PGC and GCC biology. Further, we correlated *PRAME* expression to DNA methylation and RA responsiveness and analysed how histone deacetylation affects *PRAME* expression in GCC cell lines.

Materials and methods
=====================

Ethics statement
----------------

The ethics commitee of the Rheinische Friedrich-Wilhelms-Universität Bonn approved the analyses of formalin fixed, paraffin-embedded type-II GCC tissues in context of this study. No personal patient data will be collected or stored. Written permission to use the tissue for scientific purposes was obtained from the patients and was approved by the 'Ethik-Kommission für klinische Versuche am Menschen und epidemiologische Forschung mit personenbezogenen Daten der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn\' (the ethics committee for clinical trials on humans and epidemiological research with patient-related data of the medical faculty of the Rheinischen-Friedrich-Wilhelms-University Bonn; 065/12 to GK).

Cell culture
------------

All GCC cell lines used in this study were cultured as described previously ([@bib14], [@bib15]). Briefly, TCam-2 and NCCIT were cultured in RPMI medium and 2102EP, NT2/D1, 833KE, H12, GCT27, 1777N, JAR, JEG-3 in DMEM. MPAF, ARZ and EMF (provided by Dr Michael Peitz (Life & Brain, Department of Reconstructive Neurobiology, Bonn, Germany)) as well as FS1 (provided by Dr Valerie Schumacher (Harvard Medical School, Department of Pediatrics, Boston, MA, USA) ([@bib22]) were grown in DMEM medium (10% FCS (20% FS1), 1% penicillin/streptomycin, 200 m[M L]{.smallcaps}-glutamine, 1 × non-essential amino acids, 100 n[M]{.smallcaps} β-mercaptoethanol) at 37 °C and 5% CO~2~.

Tissue microarrays
------------------

Tissue microarrays were assembled and prepared in house after approval by the internal review board. Further information is given in the study by [@bib15]). All tumours were classified according to the WHO classification based on their histology. Samples were examined by frozen section to assure a significant tumour cellularity. In total, 69 seminomas and 33 ECs were analysed. Only TFAP2C-positive/SOX2-negative seminomas and SOX2-positive ECs were analysed.

DNA, RNA and protein isolation
------------------------------

DNA, RNA and proteins were isolated as described previously ([@bib15]). DNA was isolated by phenol/chloroform/isoamylalcohol, RNA by the RNeasy Mini kit (Qiagen, Hilden, Germany). Bulk proteins were isolated by RIPA buffer, whereas nuclear and cytoplasmic proteins were separately isolated by the 'Nuclear Extract Kit\' (Active Motif, La Hulpe, Belgium) according to the manual.

Western blot
------------

Western blots analyses were performed as described previously ([@bib15]). The Mini-PROTEAN Electrophoresis Cell and Trans-Blot Turbo system were used (BioRad, Munich, Germany). Gels were blotted onto PVDF membranes. Chemiluminescent signals were detected using ChemiDoc MP Imaging System (BioRad). β-Actin was used as housekeeper and for data normalisation. See [Table 1](#tbl1){ref-type="table"} for antibody details. Colorimetric analysis of band/expression intensities was performed by Image Lab software (BioRad).

Quantitative RT-PCR
-------------------

Quantitative RT-PCR (qRT-PCR) was performed as described previously ([@bib15]). For first strand synthesis, the RevertAid First Strand cDNA Synthesis Kit manual (Fermentas, St Leon-Rot, Germany) was used. For PCR, the Maxima SYBR Green qPCR Master Mix (Fermentas, St Leon-Rot, Germany) was used. PCR was performed using the ViiA 7 Real Time PCR System (Applied Biosystems, distributed by Life Technologies, Carlsbad, CA, USA). Each qRT-PCR analysis for each biological replicate was performed in three technical replicates. At the end of each PCR run, a melting point analysis was performed. *GAPDH* was used as housekeeping gene and for data normalisation. See [Table 2](#tbl2){ref-type="table"} for primer sequences.

Immunohistochemistry and immunofluorescence staining
----------------------------------------------------

IHC was performed as published previously ([@bib15]). Tumour tissues were dissected, fixed in 4% formalin overnight and processed in paraffin wax. Signal detection was performed semi-automatically in the Autostainer 480S (Medac, Hamburg, Germany). Nuclei were stained by hematoxylin. IF was performed as described previously ([@bib13], [@bib15]). Nuclei were stained by Hoechst 33342. See [Table 1](#tbl1){ref-type="table"} for antibody details and dilution ratios.

PathScan array
--------------

A PathScan Intracellular Signaling Array was performed as published and according to the manufacturer\'s manual (Cell Signaling Technology, via NEB, Frankfurt am Main, Germany; [@bib16]). In all, 70 *μ*g of total protein was loaded onto the array and incubated at 4 °C overnight. Each sample was analysed in three biological replicates.

Sodium-bisulfite treatment
--------------------------

Sodium-bisulfite sequencing was performed as described previously ([@bib11]). Briefly, 500 ng of DNA were sodium-bisulfite-converted using the EZ DNA-Methylation Gold kit (Zymo Research, Freiburg, Germany). Each sample was analysed in five replicates. See [Table 2](#tbl2){ref-type="table"} for PCR primer details.

RA and HDI treatment of GCC cell lines
--------------------------------------

RA treatment was performed as described previously ([@bib12]). 1 × 10^5^ GCC cells were treated for 8 days (d) with 20 *μ*[M]{.smallcaps} RA (Sigma-Aldrich, Taufkirchen, Germany), as well as for 16 h with 10 n[M]{.smallcaps} romidepsin (Celgene, Signal Pharmaceuticals, San Diego, CA, USA) for 24 h with 1 *μ*[M]{.smallcaps} SAHA, for 24 with 1 *μ*[M]{.smallcaps} VPA and for 24 h with 20 n[M]{.smallcaps} TSA (all from Sigma-Aldrich). Corresponding solvents were used as controls, that is, DMSO.

Retroviral transduction of *PRAME* shRNA
----------------------------------------

The *PRAME* shRNA oligonucleotides ([Table 2](#tbl2){ref-type="table"}) were cloned into the pSUPER.retro.puro-vector (OligoEngine, Seattle, WA, USA) according to the pSUPER RNAi System manual. A shRNA against the GFP sequence was used as unspecific control. A plasmid coding for GFP (pRP-GFP) was utilised to monitor the infection efficiency. Retroviral particles were produced in 1.2 × 10^6^ HEK293 cells by transfecting 2 *μ*g of the retroviral PRAME shRNA plasmid, 2 *μ*g pCMV-gag-pol-plasmid and 220 ng pCMV-VSV-G-plasmid via the calcium phosphate method. The next day, medium was replaced by fresh medium. On day 3, the supernatant was harvested, sterile filtered and applied to the target cells. Stable shRNA-expressing cells were selected by adding 0.5 mg ml^−1^ puromycin every second day for 1 week.

Expression microarray analysis
------------------------------

Illumina HT-12v4 expression microarray analysis of GCC cell lines and *PRAME* knockdown of cells were performed as described previously ([@bib15]). All microarray data are publically available ([ncbi.nlm.nih.gov/geo/](http://ncbi.nlm.nih.gov/geo/)) (GSE71269). Each sample was analysed in three replicates. Affymetrix expression microarray data of GCC tissues have been re-analysed in context of this study ([@bib5]). In total, 4 normal testis tissues, 3 GCNIS, 4 seminomas, 3 ECs and 3 teratomas were analysed.

Chromatin-immunoprecipation followed by sequencing analysis
-----------------------------------------------------------

Chromatin-immunoprecipation followed by sequencing (ChIP-seq) analysis was performed by Active Motif (Carlsbad, CA, USA) in context of a different study and was re-analysed in this study with regard to *PRAME*. Genomic DNA of TCam-2 cells, including *Drosophila* DNA as spike-in control were used as input control. The ChIP-seq data are publically available via GEO (GSE78262).

STRING and DAVID analysis and Venn diagrams
-------------------------------------------

STRING protein--protein interaction prediction were performed online using default settings ([string-db.org](string-db.org); [@bib25]). DAVID-based functional annotation analysis was also performed online using highest classification stringency setting ([david.ncifcrf.gov](david.ncifcrf.gov); [@bib9]). Venn diagrams were generated using 'Venny\' ([bioinfogp.cnb.csic.es/tools/venny](bioinfogp.cnb.csic.es\tools\venny)).

Results
=======

CTAs are expressed in testis and cancer tissues. Using expression microarray analysis, we first compared expression of CTAs in GCC cell lines ([Supplementary Data S1A](#sup1){ref-type="supplementary-material"}). We excluded all CTAs with expression intensity similar or lower than that of *SOX2* in TCam-2 cells (log~2~7.5). We found members of the *MAGE* (A3, A6, A8, A12) and *GAGE* (2B, 2E, 4, 5, 6, 7,12B, 12C, 12F, 12G, 12H, 12I, 12J) family highly expressed in choriocarcinoma-like JAR cells, whereas seminomatous TCam-2 cells strongly express *PRAME* and *XAGE* family members (1, 1A, 1B, 1C, 2B (also high in JAR); [Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}). Seven other CTAs, that is, *MAGE* members (D1, D2, E1, F1), *SPA17*, *MORC2* and *TDRD1* are commonly expressed in all analysed GCC cell lines ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}). Expression of none of the CTA members reached significance level in both EC cell lines (2102EP, NCCIT; [Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}).

Next, we compared expression of CTAs in normal adult testis tissues and GCC tissues ([Supplementary Data S1B](#sup1){ref-type="supplementary-material"}). We excluded all CTAs with expression intensity equivalent or lower than that of *SOX2* in seminomas (log~2~9.7). A total of 53 CTAs were found significantly expressed in normal adult testis tissues, 33 in GCNIS, 25 in seminomas and 23 in ECs ([Supplementary Data S1B](#sup1){ref-type="supplementary-material"}). Again, we found the CTAs *PRAME* and *XAGE1* strongly expressed in GCNIS/seminomas, but not in ECs.

Type II GCC are thought to originate from a developmentally arrested PGC ([@bib18]). GCNIS/seminomas resemble PGCs in terms of gene expression and morphology, whereas ECs are similar to embryonic stem cells. To analyse, if *PRAME* is also expressed in PGCs, we performed a meta-analysis of RNA-sequencing data of human PGCs (male and female; weeks 5.5, 7, 9, 19 of gestation), human PGC-like cells, human embryonic stem cells, gonadal somatic cells and TCam-2 performed by [@bib7], [@bib7] and [@bib26]. *PRAME* is expressed in human PGCs of all gestational weeks analysed and seminoma (TCam-2) cells, but not detectable in somatic cells, human embryonic stem cells or human PGC-like cells ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}). Of note, aside expression of *PRAME* in TCam-2, no other *PRAME* family member (*PRAMEF1*--*22*) is expressed in GCC cell lines, fibroblasts (MPAF) or Sertoli cells (FS1; [Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}).

These data indicate that the CTA *PRAME* is expressed in PGC/GCNIS/seminoma and demarcates these entities from ECs. Further, we observed downregulation of *PRAME* in seminomatous TCam-2 after xenografting into the somatic microenvironment of the murine flank, where they reprogram to an EC-like fate ([@bib15]). This reprogramming process is associated by a rapid induction of SOX2 and downregulation of SOX17 ([@bib15]).

Our data indicate that PRAME is expressed in PGCs, GCNIS and seminomas, and like SOX17, can be utilised to discriminate GCNIS/seminomas from ECs/non-seminomas. Next, we compared *PRAME* expression with *SOX2* and *SOX17* expression in normal adult testis tissues, GCNIS, seminomas, ECs and teratomas. We demonstrated that *PRAME* expression is high in normal adult testis tissues, GCNIS and seminomas, but low in ECs ([Figure 1A](#fig1){ref-type="fig"}; [@bib4]). In GCC tissues, *PRAME* expression correlated to *SOX17* and inversely correlated to *SOX2* expression, suggesting that in GCNIS/seminomas PRAME might be functionally linked to SOX17 ([Figure 1A](#fig1){ref-type="fig"}).

We next compared *PRAME* expression and protein level between seminomas and ECs as well as corresponding cell lines by qRT-PCR and western blot analysis (HPA045153, [Table 1](#tbl1){ref-type="table"}; [Figure 1B and C](#fig1){ref-type="fig"}). We found high levels of PRAME in seminomas/TCam-2, whereas expression was negligible in EC, choriocarcinoma cell lines, fibroblast and Sertoli cells. ([Figure 1B and C](#fig1){ref-type="fig"}). By use of a second PRAME antibody (H-10, [Table 1](#tbl1){ref-type="table"}), we verified PRAME expression in TCam-2 cells and absence in 2102EP ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}). In addition, we performed IHC of GCC tissue microarrays containing 69 pure seminoma and 33 EC tissues ([Figure 1D](#fig1){ref-type="fig"}). Only TFAP2C-positive and SOX2-negative seminomas, and SOX2-positive ECs were analysed ([Supplementary Figure S2B](#sup1){ref-type="supplementary-material"}). Seminomas displayed a strong signal of PRAME in the cytoplasm and the nucleus ([Figure 1D](#fig1){ref-type="fig"}, 45% E, PRAME 1) or in the cytoplasm only ([Figure 1D](#fig1){ref-type="fig"}, 55% E, PRAME 2), whereas all ECs displayed only very weak to negligible cytoplasmic staining ([Figure 1D](#fig1){ref-type="fig"}, 100% E, PRAME 3/4). In ECs, no nuclear PRAME staining could be detected ([Figure 1D and E](#fig1){ref-type="fig"}, PRAME 3/4). This antibody staining (HPA045153, [Table 1](#tbl1){ref-type="table"}) was verified by the use of a second antibody detecting PRAME (ab89097, [Table 1](#tbl1){ref-type="table"}) and yielded comparable results, that is, nuclear and/or cytoplasmic staining in seminomas ([Supplementary Figure S2C](#sup1){ref-type="supplementary-material"}, PRAME 5/6) and only weak cytoplasmic staining of PRAME in ECs ([Supplementary Figure S2C](#sup1){ref-type="supplementary-material"}, PRAME 7/8). Cytoplasmic/membranous and nuclear localisation of PRAME in TCam-2 cells was confirmed by immunofluorescence (IF) staining ([Supplementary Figure S2D](#sup1){ref-type="supplementary-material"}). As negative control, we stained human placenta tissue for PRAME and found a weak signal in the cytoplasm of trophoblast cells. So, in IHC the antibodies seem to give rise to an unspecific cytoplasmic staining ([Supplementary Figure S2C](#sup1){ref-type="supplementary-material"}, PRAME 9/10). To test, whether a specific cytoplasmic PRAME signal can be detected by western blotting, we isolated cytoplasmic and nuclear proteins of TCam-2 cells. Efficient separation of both fractions was shown by detection of OCT3/4 (nuclear) and β-Actin (cytoplasmic; [Figure 1F](#fig1){ref-type="fig"}). A signal at 58 kDa corresponding to the expected size of the PRAME protein was detectable in both, the cytoplasm and the nucleus ([Figure 1F](#fig1){ref-type="fig"}). As in IF, a more prominent signal was detected in the nucleus. Thus, in western blotting the antibody is able to specifically detect PRAME, but IHC staining is biased by detection of additional unspecific signals in the cytoplasm.

To analyse the molecular consequences of a *PRAME* knockdown in TCam-2 cells, we established a shRNA knockdown using retroviral vectors. The fact that \>95% of the cells were positive for GFP after infection of TCam-2 cells with GFP-coding viral particles demonstrates an efficient transduction procedure ([Figure 2A](#fig2){ref-type="fig"}; pRP-GFP). In TCam-2, qRT-PCR and western blot analyses demonstrated that the *PRAME* knockdown level was on average 81% (shRNA1.1: 80%, 1.2: 80%, 1.3: 83% [Figure 2B and C](#fig2){ref-type="fig"}). To screen for dose-dependent effects, a further *PRAME* shRNA (shRNA 2) was used that reduced *PRAME* mRNA levels to ∼50% ([Figure 2D](#fig2){ref-type="fig"}). One week post infection and antibiotic selection, stable PRAME shRNA-expressing clones emerged. These clones had changed morphology to a more flattened, roundish shape with an increased cell size, suggesting that they had initiated differentiation ([Figure 2A](#fig2){ref-type="fig"}).

In order to reveal the molecular effects of a PRAME knockdown, we performed expression microarray analyses.

The *in vivo* reprogramming of TCam-2 to an EC-like state is accompanied by rapid downregulation of *PRAME*, which is suggested to antagonise RA signalling by binding and blocking RA receptors ([@bib6]; [@bib15]). During the reprogramming, we observed upregulation of RA-signalling-associated factors (*RBP1*, *CRABP1*/*2*, *FABP5* and *CYP16A1*; [@bib15]). In addition, RNAi-mediated knockdown of *PRAME* in melanoma cells restores RA sensitivity ([@bib6]). Thus, knockdown of *PRAME* might render TCam-2 cells sensitive toward RA. Therefore, we analysed the TCam-2-knockdown cells±RA.

We sorted the data for genes significantly deregulated (threshold log~2~1.5) in *PRAME* shRNA TCam-2 cells ([Figure 3A](#fig3){ref-type="fig"}, [Supplementary Data S1C](#sup1){ref-type="supplementary-material"}) and utilised the DAVID algorithm to predict enriched gene categories and found 12 clusters enriched, when analysing the upregulated genes ([Supplementary Data S1D](#sup1){ref-type="supplementary-material"}). With the highest enrichment score (⩾0.86), categories associated with reproductive structure development, development of primary sexual characteristics and sex differentiation were enriched. In addition, categories related to cell adhesion and migration, regulation of kinase activity/phosphorylation and muscle development were detected. The DAVID analysis suggests that PRAME is normally involved in repression of these processes.

We found 14 clusters, when analysing the downregulated genes ([Supplementary Data S1E](#sup1){ref-type="supplementary-material"}). With a highest enrichment score (⩾1.83), categories related to leucine-zipper transcription factors and regulation of apoptosis were enriched ([Supplementary Data S1E](#sup1){ref-type="supplementary-material"}).

We used the STRING-algorithm to predict protein-interactions between all genes up- or downregulated after *PRAME* knockdown ([Figure 3B and C](#fig3){ref-type="fig"}). STRING-predicted interaction of *LIN28A* and *PRDM14* with *ZSCAN10* ([Figure 3C](#fig3){ref-type="fig"}, downregulated). Like *LIN28A* and *PRDM14, ZSCAN10 (zinc-finger* and *SCAN domain-containing 10,* aka *ZFP206*) is a pluripotency-associated factor and involved in the regulation of *Oct3/4*, *Nanog*, *Sox2*/*Sox17* and *Sall4* in murine embryonic stem cells ([@bib33]; [@bib30]). So, three regulators of pluripotency (*LIN28A*, *PRDM14* and *ZSCAN10*) are downregulated upon *PRAME* knockdown, suggesting that PRAME normally contributes to maintenance of the pluripotency programme in TCam-2 cells.

Among the genes upregulated after *PRAME* knockdown are several factors related to endodermal and/or mesodermal differentiation processes, such as *IGFBP5*, *OSR1*, *NR2F2*, *TGFB1*, *GPC3*, *SOX21*, *CD34* and *TP63* ([Figure 3A](#fig3){ref-type="fig"}). In line, our DAVID analysis detected enrichment of genes associated with muscle development (mesoderm; [Supplementary Data S1D](#sup1){ref-type="supplementary-material"}). These findings suggest that *PRAME* shRNA cells initiate differentiation into the somatic lineage.

Furthermore, knockdown of *PRAME* led to upregulation of genes associated with reproductive development and germ cell differentiation (*CCND1*, *DMRT1*, *OSR1*, *TP63*, *SPRY4*), indicating that PRAME suppresses this programme ([Supplementary Data S1D](#sup1){ref-type="supplementary-material"}).

In summary, our data demonstrate that in TCam-2 *PRAME* supports the pluripotency network and suppresses a somatic and germ cell differentiation process.

We hypothesised that a *PRAME* knockdown might render TCam-2 cells sensitive towards RA. However, the expression levels of all deregulated genes were highly comparable between TCam-2 *PRAME* shRNA cells with or without RA treatment, suggesting that RA has minor effects on expression of indicated genes ([Figure 3A](#fig3){ref-type="fig"}). In total, we found only 19 microarray probes (coding for 14 annotated genes) differentially expressed between RA-treated and -untreated *PRAME* shRNA cells ([Supplementary Data S1C](#sup1){ref-type="supplementary-material"}). Among them, RA-signalling-related genes *CYP26A1*, *CYP26B1*, *HOXA5* and *RARB*. Interestingly, genes upregulated in PRAME shRNA cells showed also a trend towards upregulation in RA-treated TCam-2 cells, but expression intensities were mostly below our significance threshold level ([Figure 3A](#fig3){ref-type="fig"}). In contrast, expression of the majority of genes downregulated in *PRAME* shRNA cells were not affected in RA-treated TCam-2 cells ([Figure 3A](#fig3){ref-type="fig"}). After RA treatment of TCam-2 cells, we found only 23 genes significantly deregulated in expression (22 upregulated, 1 downregulated; [Supplementary Data S1C](#sup1){ref-type="supplementary-material"}), including RA-signalling-related genes *CYP26A1*, *CYP26B1*, *HOXA5*, *RARB*, which were also upregulated in RA-treated *PRAME* shRNA cells.

We verified that the RA concentration applied in our experiments (20 μ[M]{.smallcaps}) is sufficient to induce differentiation in the EC cell lines NT2/D1 and NCCIT. A qRT-PCR analysis 8 days (d) after RA treatment demonstrates that both cell lines downregulated typical EC markers and pluripotency factors (*NANOG*, *OCT3/4*, *SOX2*, *GDF3*, *DNMT3B*, *DNMT3L*) and induced expression of mesodermal differentiation factors *PAX6* and *HAND1*, as well as RA receptors *RARA* and *RARB* ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}).

These findings demonstrate that a *PRAME* knockdown does not sensitise TCam-2 cells towards a RA-induced differentiation process, although upregulation of RA-response genes, like *RARB* demonstrated a cellular response toward RA.

Using qRT-PCR, we verified selected deregulations found by the microarray analysis. As already demonstrated, in *PRAME* shRNA cells we detected downregulation of *PRAME*, *LIN28A*, *DNMT3L*, *PRDM14*, *ATF3* and *GAL*, whereas *DUSP6*, *DMRT1* and *CCDN1* were upregulated ([Figure 3D](#fig3){ref-type="fig"}). By western blotting, we confirmed downregulation of PRDM14 in *PRAME* shRNA cells ([Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}).

We screened for expression of further pluripotency and epigenetic reprogramming-related factors, because downregulation of *LIN28A*, *PRDM14* and *ZSCAN10* might influence expression of other pluripotency factors. We found downregulation of pluripotency factors *NANOG*, *OCT3/4*, *SALL4*, *ZIC3, DPPA3, DPPA5, REX1* as well as of the *de novo* DNA methyltransferase *DNMT3A* ([Figure 3D](#fig3){ref-type="fig"}). Expression of the maintenance DNA methyltransferase *DNMT1* was not considerably changed ([Figure 3D](#fig3){ref-type="fig"}). The qRT-PCR analysis confirmed that addition of RA had no significant impact on the expression of the analysed pluripotency-, PGC- and differentiation-associated genes ([Figure 3D](#fig3){ref-type="fig"}). Although, *RARB* was strongly induced in RA-treated samples, indicating that RA indeed stimulates *RAR* receptor expression, but obviously without any effect on the differentiation status of TCam-2 cells ([Figure 3D](#fig3){ref-type="fig"}).

To analyse whether the observed effects are dose-dependent, we analysed the expression of pluripotency factors in TCam-2 cells showing 80% and 50% knockdown of *PRAME* ([Figures 2B](#fig2){ref-type="fig"} and [3E](#fig3){ref-type="fig"}). In a dose-dependent manner, we demonstrated the downregulation of *NANOG*, *OCT3/4*, *LIN28A*, *SALL4, REX1* and *PRDM14*, as well as PGC markers *DPPA3*, *PRDM1* and *TFAP2C*. Downregulation of OCT3/4, LIN28A and TFAP2C was verified by western blotting ([Supplementary Figure S3C](#sup1){ref-type="supplementary-material"}).

The deregulations in expression of pluripotency/PGC factors were also detected by our microarray analysis, but expression intensities were slightly below our set significance threshold. Nevertheless, the same trend in downregulation of pluripotency factors was found ([Supplementary Figure S3D](#sup1){ref-type="supplementary-material"}).

During human PGC specification, PRDM1 and TFAP2C are regulated by SOX17, whereas in murine embryonic stem cells SOX17 drives endodermal differentiation ([@bib1]; [@bib10]). Upon *PRAME* knockdown expression of *SOX17* did not change significantly, whereas PGC markers, *PRDM1*, *PRDM14*, *TFAP2C* and *DPPA3* were downregulated, and markers for germ cell and somatic differentiation were upregulated. This demonstrates that expression of SOX17 does not depend on PRAME. However, PRAME is required to maintain PGC-state in repressing somatic and further germ cell differentiation in TCam-2.

Furthermore, our analysis of the *PRAME* shRNA cells pointed at a regulatory link between PRAME and the RNA-binding protein LIN28A. By Co-IP analysis using either a LIN28A or a PRAME antibody, we demonstrated that indeed PRAME and LIN28A interact with each other ([Figure 3F](#fig3){ref-type="fig"}). Thus, the influence of PRAME on the pluripotency programme is at least in part a result of the interaction with LIN28A, maybe by binding and guiding LIN28A to its target RNAs.

Next, we asked if a *PRAME* knockdown affects activity of signalling pathways in TCam-2 cells ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). A PathScan intracellular signalling array analysis detected a significantly increased phosphorylation of ERK1/2, P38 and AMPK-*α* in *PRAME* shRNA cells, suggesting that PRAME normally limits activity of the corresponding pathways ([Figure 3G](#fig3){ref-type="fig"}, [Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}). By western blotting, we confirmed increased ERK1/2 signalling activity in *PRAME* shRNA cells ([Figure 3G](#fig3){ref-type="fig"}, right side; [Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}). So, knockdown of *PRAME* leads to an increase in MAPK signalling. In line, our DAVID analysis predicted enrichment of genes associated with regulation of kinase activity/phosphorylation, and by microarray analysis we found upregulation of marker genes associated with ERK1/2/P38-MAPK signalling, that is, *CYP26A1*, *IGFBP5*, *THBS1*, *CXCL14*, *GPC3*, *CCND1*, *TGFB1* as well as the negative regulators of MAPK signalling, *SPRY4* and *DUSP6,* which might limit MAPK signalling again.

Finally, we asked how expression of *PRAME* is regulated in GCC cells? In human malignancies, like acute myeloid leukaemia, *PRAME* expression is regulated by DNA methylation ([@bib21]). In addition, it has been shown that *PRAME* expression can be de-repressed by treating acute myeloid leukaemia cells with HDAC inhibitors (HDI), suggesting that *PRAME* is regulated by DNA methylation and histone acetylation ([@bib32]). By a ChIP-seq analysis of TCam-2 cells against pan-acetylated histone 3 (H3ac) and illustrating the data in the Genome Browser, we found high enrichment of H3ac around the transcription start sites (TSS) ([Figure 4A](#fig4){ref-type="fig"}, blue box). Thus, we assume that euchromatin at the *PRAME* TSS allows for expression in TCam-2.

Within the first *PRAME* TSS, a CpG-island was found ([Figure 4A](#fig4){ref-type="fig"}, blue box). We used sodium-bisulfite sequencing to analyse the DNA methylation within this region in GCCs and corresponding cell lines. Seminomas and TCam-2 cells harbour a hypomethylated *PRAME* promotor region (\<20%), whereas ECs and corresponding cell lines (2102EP, NCCIT) displayed *PRAME* hypermethylation (\>80% [Figure 4B](#fig4){ref-type="fig"}). As previously demonstrated by us, *PRAME* methylation increased during the *in vivo* reprogramming of TCam-2 to an EC-like cell fate, which is accompanied by *PRAME* downregulation ([Figure 4B](#fig4){ref-type="fig"}; TCam-2 *in vivo* 2 w, 6 w; [@bib15]). Thus, *PRAME* expression inversely correlates to the DNA methylation status of the *PRAME* promoter in GCNIS/seminomas and ECs, suggesting that *PRAME* expression is silenced by DNA methylation in non-seminomas.

It has been shown that *PRAME* expression can be de-repressed by treating acute myeloid leukaemia cells with HDI ([@bib32]). In order to check whether PRAME negative GCC cell lines would behave similarly we treated GCC cell lines with the HDI romidepsin and analysed *PRAME* expression levels by qRT-PCR analysis ([Figure 4C](#fig4){ref-type="fig"}). Adult (MPAF) and neonatal (ARZ) fibroblasts, as well as Sertoli cells (FS1) were used as controls. *PRAME* expression was upregulated in two EC cell lines (2102EP: 8.7-fold; NCCIT: 3.2-fold) and two choriocarcinoma cell lines (JAR: 1.9-fold (HDI *vs* solvent control), JEG-3: 18.0-fold), whereas *PRAME* was slightly downregulated in TCam-2 and remained nearly unchanged in fibroblasts (MPAF: 1.3-fold, ARZ: 0.7-fold), as well as Sertoli cells (FS1: 1.2-fold) ([Figure 4C](#fig4){ref-type="fig"}). We verified upregulation of PRAME in 2102EP and JAR cells, as well as nearly unchanged PRAME expression in TCam-2 and MPAF by western blotting ([Figure 4D](#fig4){ref-type="fig"}). In addition, we confirmed efficacy of the HDI treatment by demonstrating hyperacetylation of histone H3 ([Figure 4D](#fig4){ref-type="fig"}). Furthermore, we treated 2102EP and NCCIT cells with the HDI SAHA (1 *μ*[M]{.smallcaps}), VPA (1 *μ*[M]{.smallcaps}) and TSA (20 n[M]{.smallcaps}) for 24 h ([Figure 4E](#fig4){ref-type="fig"}). Both cell lines induced *PRAME* expression after the treatment, with 2102EP showing a stronger response than NCCIT ([Figure 4E](#fig4){ref-type="fig"}). In conclusion, *PRAME* expression can be restored in non-seminomatous GCC cell lines by inhibition of HDACs. So, formation of euchromatin around the PRAME locus seems to override the repressive DNA methylation mark, leading to de-repression of PRAME expression.

Discussion
==========

In this study, we analysed expression of the CTA *PRAME* in human testicular GCCs and corresponding cell lines, and demonstrated that *PRAME* is expressed in PGCs/GCNIS/seminomas and is absent in ECs. Knocking down *PRAME* in seminomatous TCam-2 leads to downregulation of pluripotency and PGC markers, as well as activation of MAPK signalling. In addition, the cells displayed increased cell size and appeared as big flat roundish cells indicative of differentiation. Expression microarray analyses revealed upregulation of genes suggestive for endodermal/mesodermal and germ cell differentiation. Thus, in seminomas (and probably in human PGCs) expression of PRAME leads to a fixation of the PGC fate by suppressing germ cell and somatic differentiation.

So, why do TCam-2 cells need *PRAME*? In the murine system, depending on the binding partner the transcription factor OCT3/4 binds to different motifs. When SOX2 is present it partners with OCT3/4 and binds to canonical motifs that are associated with pluripotency, whereas in the presence of SOX17, OCT3/4/SOX17 bind to compressed motifs which trigger endodermal differentiation ([@bib1]; [@bib29]). In addition, during specification of human PGCs, SOX17 has been described as a master regulator transactivating the PGC markers, PRDM1, PRDM14 and TFAP2C ([@bib10]; [@bib26]). These data suggest that in seminomas SOX17 is able to bind the canonical motif and thus, supports the pluripotency programme. Hence, in this case, SOX17 can replace SOX2 in the pluripotency cluster.

How is this achieved? Knockdown of *PRAME* does not affect the level of *SOX17*, whereas a downregulation of *SOX17* during the *in vivo* reprogramming is followed by the loss of *PRAME* expression ([@bib15]). This indicates that SOX17 is upstream of PRAME in the cascade of PGC genes.

Furthermore, knockdown of *PRAME* results in downregulation of pluripotency/PGC factors (*LIN28A*, *PRDM14*, *ZSCAN10*, *DPPA3*, *PRDM1*, *TFAP2C*) and upregulation of genes indicative for germ cell differentiation, *CCND1*, *DMRT1*, *OSR1*, *TP63*, *SPRY4*. This suggests that PRAME expression leads to a fixation of the SOX17-induced PGC fate.

Moreover, lowering the levels of *PRAME* led to upregulation of endoderm markers. As mentioned above, PRAME seems required for binding of the SOX17/OCT3/4 dimers to pluripotency markers. Reduction of PRAME leads to alteration in binding-site selection, allowing (as demonstrated in murine embryonic stem cells) the SOX17/OCT3/4 dimers to bind to somatic differentiation genes.

Of note, a knockdown of *PRAME* leads to increased activity of MAPK signalling (ERK1/2, P38). It is known that repression of MAPK signalling by MEK inhibition is required to maintain ES cells in pluripotency and repress somatic differentiation. It remains to be elucidated whether PRAME itself represses MAPK signalling, or whether the upregulation of MAPK signals is a secondary process due to the upregulation of somatic differentiation markers.

Treatment of the *PRAME*-knockdown TCam-2 cells with RA had no considerable effect on expression of pluripotency and PGC markers, suggesting that RA has little role in *PRAME*-knockdown-induced reduction of pluripotency and loss of a seminoma-like cell state. In *PRAME*-knockdown cells, the RA-metabolising enzyme *CYP26A1* was strongly upregulated, which might catabolise RA to excreted oxoderivatives (4-OH RA, 4-oxo RA, 18-OH RA). This leads to the suppression of RA-induced differentiation.

We found that *PRAME* expression inversely correlated to DNA methylation in the *PRAME* promoter, and that in non-seminomatous cell lines repressed *PRAME* expression can be restored by HDI treatment. In contrast to non-seminomas, seminomas respond very well to DNA-damaging treatments, that is, cisplatin-based therapies. In future experiments it would be of interest to find out if PRAME has a role in this sensitivity and if restoring *PRAME* expression by HDI treatment in (chemotherapy-resistant) non-seminomas might re-sensitise these cells towards a treatment with DNA-damaging agents.

We combined our findings and hypotheses in a model ([Figure 5](#fig5){ref-type="fig"}). In PGC/GCNIS/seminomas, the *PRAME* promoter is unmethylated and encircled by euchromatin, allowing for *PRAME* expression ([Figure 5A](#fig5){ref-type="fig"}). In the presence of PRAME, SOX17/OCT3/4 dimers bind to canonical motifs, usually occupied by SOX2/OCT3/4 dimers. This leads to expression of the pluripotency factors *LIN28A*, *PRDM14* and *ZSCAN10.* Furthermore, PRAME is downstream of SOX17 in mediating the activation of PGC factors *PRDM1*, *TFAP2C* and *DPPA3*. This leads to a fixation of the PGC cell fate. Upon knockdown of *PRAME*, SOX17 binds to compressed motifs, resulting in induction of somatic and germ cell differentiation programs ([Figure 5B](#fig5){ref-type="fig"}).
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![**PRAME expression in GCC tissues and cell lines.** (**A**) Correlation of *SOX2* and *SOX17* expression to *PRAME* expression in normal adult testis tissue (NATT) and indicated GCC tissues. (**B**) qRT--PCR analysis of *PRAME* expression in indicated GCC tissues and corresponding cell lines as well as fibroblasts (Fibro) and Sertoli cells (Sert). (**C**) Western blot analysis of PRAME expression in seminoma and EC tissues, as well as GCC cell lines and human fibroblasts. (**D**) Pie diagrams summarising cellular localisation of PRAME in seminoma and EC tissues as determined by IHC. (**E**) IHC staining of PRAME in seminomas and ECs. Scale-bars: 200 *μ*m. (**F**) Western blot analysis of PRAME expression in the nuclear and cytoplasmic extract of TCam-2 cells. Efficient separation of nuclear and cytoplasmic fraction was demonstrated by OCT3/4 and *β*-actin detection. Sem=seminomas; EC=embryonal carcinoma; Cc=choriocarcinoma.](bjc2016187f1){#fig1}

![***PRAME* shRNA-mediated knockdown in TCam-2 cells.** (**A**) Detection of a GFP signal in nearly all pRP-GFP-infected TCam-2 (pRP-GFP) demonstrates high transduction efficiency. Compared with mock infected TCam-2 (mock), *PRAME*-knockdown cells (PRAME shRNA 1) show a change in morphology, that is, increase in cell size. (**B**, **C**) qRT--PCR and western blot analysis of PRAME expression in *PRAME* shRNA-infected and puromycin-selected TCam-2 cells. In western blotting, mock-infected, GFP shRNA-infected and empty vector-infected TCam-2 served as controls.](bjc2016187f2){#fig2}

![**Analysis of gene expression dynamics and regulatory networks in TCam-2 *PRAME* shRNA cells±RA.** (**A**) Expression microarray data of probes deregulated in *PRAME* shRNA cells treated with or without RA and in RA-treated TCam-2. (**B**, **C**) STRING-based protein--protein interaction prediction of all probes upregulated (**B**) or downregulated (**C**) in *PRAME* shRNA cells. (**D**) qRT--PCR analysis of indicated marker genes in RA-treated TCam-2 and TCam-2 *PRAME* shRNA cells with and without RA application. (**E**) qRT--PCR analysis of indicated marker genes in shRNA 1- and 2-infected TCam-2 cells, showing a 80% and 50% *PRAME* knockdown. (**F**) Co-IP analysis using either a PRAME (IP PRAME) or a LIN28A (IP LIN28) antibody. Ten percent of protein lysate was used as input control (input). Dynabeads incubated with protein lysate but without any antibody were used as negative control (no ab). (**G**) PathScan analysis of indicated signalling pathway activities in *PRAME* shRNA cells (left side). A western blot analysis confirmed increased phosphorylation of ERK1/2 in *PRAME* shRNA cells (right side). Western blot raw data is given in [Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}.](bjc2016187f3){#fig3}

![**Epigenetic regulation of *PRAME* expression by DNA methylation and histone acetylation.** (**A**) Illustration of pan-H3ac ChIP-seq data in TCam-2 and genomic features of the *PRAME* locus in the Genome Browser. (**B**) Sodium-bisulfite sequencing of the *PRAME* promotor in GCC tissues and corresponding cell lines, as well as during *in vivo* reprogramming of TCam-2 to an EC-like state. (**C**) qRT--PCR analysis of *PRAME* expression in HDI (romidepsin)-treated GCC cell lines, human fibroblasts (MPAF, ARZ) and human Sertoli cells (FS1). Fold change (romidepsin-treated versus solvent control) is indicated above bars. (**D**) Western blot analysis of PRAME and pan-Histone H3 acetylation (pan-H3ac) in selected HDI-treated samples. (**E**) qRT--PCR analysis of PRAME expression in HDI (SAHA, VPA, TSA)-treated 2102EP and NCCIT cells.](bjc2016187f4){#fig4}

![**Model of the cellular mechanisms of PRAME.** (**A**) Regulation of pluripotency, PGC-ness and differentiation by PRAME, SOX17 and OCT3/4 in PGCs, GCNIS and seminomas. (**B**) A knockdown of PRAME leads to suppression of pluripotency- and PGC-associated factors, whereas expression of somatic and germ cell differentiation markers is induced via binding of SOX17/OCT3/4 to compressed binding motifs.](bjc2016187f5){#fig5}

###### Antibodies used in this study

                                **Company**                    **Clone/order no.**   **Western blot**   **IHC**   **IF**
  ----------------------------- ----------------------------- --------------------- ------------------ --------- ---------
  **Primary antibody**                                                                                           
  *β*-Actin                     Sigma-Aldrich                         AC-15             1 : 20 000        ---       ---
  ERK1/2 (phospho)              Cell Signaling Technologies           9101               1 : 1000         ---       ---
  ERK1/2 (total)                Cell Signaling Technologies           9102               1 : 1000         ---       ---
  LIN28                         R&D Systems                          AF3757              1 : 500          ---       ---
  OCT3/4                        Santa Cruz Biotechnology               C10               1 : 500          ---       ---
  pan-H3ac                      Active Motif                          39139              1 : 500          ---       ---
  PRAME                         Sigma-Aldrich                       HPA045153            1 : 500        1 : 200   1 : 200
  PRAME                         Abcam                                ab89097             1 : 500        1 : 200     ---
  PRAME                         Santa Cruz Biotechnology              H-10               1 : 300        1 : 200     ---
  TFAP2C                        Santa Cruz Biotechnology              6E/4               1 : 600          ---       ---
  **Secondary antibody**                                                                                         
  Anti-mouse HRP                Invitrogen                          61--0120             1 : 1000         ---       ---
  Anti-rabbit HRP               Invitrogen                          65--6120             1 : 2000         ---       ---
  Anti-goat HRP                 Invitrogen                          61--1620             1 : 2000         ---       ---
  Alexa Fluor 488 Anti-rabbit   Invitrogen                           A11070                ---            ---     1 : 400

Abbreviations: IF=immunofluorescence; IHC=immunohistochemistry.

###### Oligonucleotides used in this study

  **Gene**            **Forward primer**               **Reverse primer**                **Tan**  **Cycles**
  ------------------- -------------------------------- -------------------------------- --------- ------------
  *ATF3*              5′-AAGAACGAGAAGCAGCATTTGAT-3′    5′-TTCTGAGCCCGGACAATACAC-3′        60 °C   40
  *CCND1*             5′-GGCGGATTGGAAATGAACTT-3′       5′-TCCTCTCCAAAATGCCAGAG-3′         60 °C   40
  *DMRT1*             5′-AGGGAAACCAAGCCAGAATC-3′       5′-TGCCCCAGTTCTTCACTTTT-3′         60 °C   40
  *DNMT1*             5′-ACCTGGCTAAAGTCAAATCC-3′       5′-ATTCACTTCCCGGTTGTAAG-3′         60 °C   40
  *DNMT3A*            5′-ACTACATCAGCAAGCGCAAG          5′-CATCCACCAAGACACAATGC-3′         60 °C   40
  *DNMT3B*            5′-CCAGCTCTTACCTTACCATC-3′       5′-CAGACATAGCCTGTCGCTTG-3′         56 °C   40
  *DNMT3L*            5′-GCCGTACACAAGATCGAAGG-3′       5′-TTTGGGCTTTTTGGAAAGTG-3′         60 °C   40
  *DPPA3*             5′-GCCACTCAACTCTCTGAAAT-3′       5′-ACTAGGGTTGAGAGTCAAGT-3′         60 °C   40
  *DPPA5*             5′-ATGGGAACTCTCCCGGCACG-3′       5′-TCACTTCATCCAAGGGCCTA-3′         60 °C   40
  *DUSP6*             5′-GCAGCGACTGGAACGAGAAT-3′       5′-ACTGAAGCCACCTTCCAGGTA-3′        60 °C   40
  *GAL*               5′-CTGGTGAGGCCATTCTTGTC-3′       5′-AAGGAAAAACGAGGCTGGAC-3′         60 °C   40
  *GAPDH*             5′-TGCCAAATATGATGACATCAAGAA-3′   5′-GGAGTGGGTGTCGCTGTTG-3′          60 °C   40
  *ID1*               5′-TCCAGCACGTCATCGACTAC-3′       5′-TCAGCGACACAAGATGCG-3′           60 °C   40
  *ID2*               5′-TCAGCCTGCATCACCAGAGA-3′       5′-CTGCAAGGACAGGATGCTGATA-3′       60 °C   40
  *ID3*               5′-TCAGCTTAGCCAGGTGGAAATC-3′     5′-TGGCTCGGCCAGGACTAC-3′           60 °C   40
  *LIN28*             5′-TTCGGCTTCCTGTCCATGAC-3′       5′-CCACTGCCTCACCCTCCTT-3′          60 °C   40
  *NANOG*             5′-CGGAGACTGTCTCTCCTCTTCC-3′     5′-GGTAGGTGCGAGGCCTTCTGC-3′        60 °C   40
  *OCT3/4*            5′-GGGAGATTGATAACTGGTGTGTT-3′    5′-GTGTATATCCCAGGGTGATCCTC-3′      60 °C   40
  *PRAME*             5′-CGTAGACTCCTCCTCTCCCACAT-3′    5′-TGGGCGATATACTGCTCTTCCT-3′       60 °C   40
  *PRAME-Bisulfite*   5′-TTTTGAATGTAGGGAAAGTAGG-3′     5′-AAGGGTAGGGGTATTTTTTTTA-3′       55 °C   40
  *PRDM1*             5′-GGGTGCAGCCTTTATGAGTC-3′       5′-CCTTGTTCATGCCCTGAGAT-3′         60 °C   40
  *PRDM14*            5′-TCCACACAGGGGGTGTACTT-3′       5′-GAGCCTTCAGGTCACAGAGC-3′         60 °C   40
  *RARB*              5′-CTCTGTGCATTCTTGCTTCG-3′       5′-CCAGGAATCGATGCCAATAC-3′         60 °C   40
  *REX1*              5′-TGCCTAGTGTGCTGGTGGT-3′        5′-GGTGGCATTGGAAATAGCAG-3′         60 °C   40
  *SALL4*             5′-GTCATTCCCTGGGTGGTTC-3′        5′-AGCACATCAACTCGGAGGAG-3′         60 °C   40
  *SOX17*             5′-GGCGCAGCAGAATCCAGA-3′         5′-CCACGACTTGCCCAGCAT-3′           60 °C   40
  *TFAP2C*            5′-GGCCCAGCAACTGTGTAAAGA-3′      5′-GCAGTTCTGTATGTTCGTCTCCAA-3′     60 °C   40
  *ZIC3*              5′-GCCAGTTCAGGCTATGAATC-3′       5′-TGCTAGTTTGAACTGCAGAA-3′         60 °C   40

  ----------------- ------------------------------------------------------------------------------
  *PRAME shRNA 1*   5′-GATCCCCAGACAAATGTTCAGTGTGATTTTCAAGAGAAATCACACTGAACATTTGTCTTTTTTA-3′
  *PRAME shRNA 2*   5′-GATCCCCGTTCCATTCAGAGCCGATACATCATTCAAGAGATGATGTATCGGCTCTGAATGGAACTTTTTA-3′
  ----------------- ------------------------------------------------------------------------------
